Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers.

bioRxiv : the preprint server for biology·2026
Same author

<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicity.

Journal of enzyme inhibition and medicinal chemistry·2026
Same author

Host-directed antiviral strategy targeting prohibitins: Mel56 suppresses influenza A virus and severe acute respiratory syndrome coronavirus 2 via modulation of antioxidant pathways and mitochondrial function.

Microbiology spectrum·2026
Same author

Second-generation prokineticin PKR<sub>1</sub> receptor agonists: Advancing cardioprotection against chemotherapy-induced toxicity.

British journal of pharmacology·2026
Same author

Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients.

JACC. Basic to translational science·2026
Same author

Development of capsaicin-derived prohibitin ligands to modulate the Aurora kinase A/PHB2 interaction and mitophagy in cancer cells.

Communications biology·2026

Related Experiment Video

Updated: Jun 6, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

Novel flavaglines displaying improved cytotoxicity.

Frédéric Thuaud1, Nigel Ribeiro, Christian Gaiddon

  • 1Therapeutic Innovation Laboratory (UMR 7200), Department of Medicinal Chemistry, Faculté de Pharmacie, CNRS-Université de Strasbourg, Illkirch, France.

Journal of Medicinal Chemistry
|December 15, 2010
PubMed
Summary

Novel flavagline analogues show potent anticancer activity by enhancing cytotoxicity. Modifications at specific structural positions, like C-1, significantly boost effectiveness and reduce tumor growth without toxicity.

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

Published on: September 26, 2019

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Related Experiment Videos

Last Updated: Jun 6, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

Published on: September 26, 2019

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Area of Science:

  • Medicinal Chemistry
  • Natural Products Chemistry
  • Pharmacology

Background:

  • Flavaglines are a class of natural products with potential anticancer properties.
  • Understanding structure-activity relationships is crucial for developing effective cancer therapeutics.
  • Multidrug resistance remains a significant challenge in cancer treatment.

Purpose of the Study:

  • To synthesize novel flavagline analogues.
  • To investigate the cytotoxicity and structure-activity relationships of these analogues.
  • To identify compounds with enhanced anticancer potential and reduced multidrug resistance effects.

Main Methods:

  • Chemical synthesis of flavagline analogues with targeted structural modifications.
  • In vitro cytotoxicity assays to evaluate compound efficacy.
  • In vivo studies using an allograft model to assess tumor growth reduction.

Main Results:

  • Introduction of substituents at the C-2 position negatively impacted multidrug resistance.
  • Replacing the C-1 hydroxy group with an aminoformyl group of opposite configuration enhanced cytotoxicity.
  • A lead compound demonstrated significant tumor growth reduction in an allograft model at non-toxic doses.

Conclusions:

  • Structural modifications of flavaglines can significantly modulate their anticancer activity and multidrug resistance profile.
  • The identified C-1 modified analogue represents a promising candidate for further development as an anticancer agent.
  • This study provides critical insights into the design of novel flavagline-based cancer therapeutics.